Jubilant Pharmova Limited (NSE:JUBLPHARMA)
India · Delayed Price · Currency is INR 970.00
+7.30 (0.76%)
Aug 11, 2026, 3:30 PM IST
Jubilant Pharmova Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 86,162 | 82,796 | 72,345 | 67,029 | 62,817 | 61,302 | |
Revenue Growth | 16.38% | 14.45% | 7.93% | 6.71% | 2.47% | 0.52% |
Cost of Revenue | 30,148 | 28,843 | 25,357 | 23,513 | 20,816 | 14,880 |
Gross Profit | 56,014 | 53,953 | 46,988 | 43,516 | 42,001 | 46,422 |
Selling, General & Admin | 29,303 | 27,679 | 23,431 | 22,873 | 22,151 | 20,739 |
Other Operating Expenses | 14,450 | 13,676 | 11,803 | 11,593 | 12,011 | 13,621 |
Operating Expenses | 48,449 | 45,759 | 38,920 | 38,285 | 38,252 | 38,023 |
Operating Income | 7,565 | 8,194 | 8,068 | 5,231 | 3,749 | 8,398 |
Interest Expense | -2,066 | -2,014 | -2,209 | -2,564 | -1,686 | -1,382 |
Interest & Investment Income | 252 | 252 | 366 | 261 | 98 | 24.51 |
Earnings From Equity Investments | -2 | -3 | -5 | 511 | 123 | -99.83 |
Currency Exchange Gain (Loss) | 219 | 219 | 6 | -42 | 172 | -464.53 |
Other Non Operating Income (Expenses) | 54 | 54 | 2 | -5 | -83 | 14.45 |
EBT Excluding Unusual Items | 6,022 | 6,702 | 6,228 | 3,392 | 2,373 | 6,491 |
Merger & Restructuring Charges | -535 | -535 | -1,450 | -2,196 | - | - |
Gain (Loss) on Sale of Investments | 31 | 31 | -17 | 2 | -50 | 1.47 |
Gain (Loss) on Sale of Assets | - | - | - | - | -27 | -33.7 |
Asset Writedown | - | - | -1,194 | - | -1,450 | -153.83 |
Other Unusual Items | -57 | -57 | 6,239 | 507 | -568 | - |
Pretax Income | 5,461 | 6,141 | 9,806 | 1,705 | 278 | 6,304 |
Income Tax Expense | 1,947 | 2,166 | 1,443 | 978 | 927 | 2,174 |
Earnings From Continuing Operations | 3,514 | 3,975 | 8,363 | 727 | -649 | 4,130 |
Net Income to Company | 3,514 | 3,975 | 8,363 | 727 | -649 | 4,130 |
Minority Interest in Earnings | 7 | 10 | 31 | 44 | 39 | 9.2 |
Net Income | 3,521 | 3,985 | 8,394 | 771 | -610 | 4,139 |
Net Income to Common | 3,521 | 3,985 | 8,394 | 771 | -610 | 4,139 |
Net Income Growth | -23.49% | -52.53% | 988.72% | - | - | -50.48% |
Shares Outstanding (Basic) | 158 | 158 | 158 | 159 | 159 | 159 |
Shares Outstanding (Diluted) | 159 | 159 | 159 | 159 | 159 | 159 |
Shares Change | -0.04% | 0.01% | 0.01% | -0.18% | -0.02% | -0.06% |
EPS (Basic) | 22.23 | 25.15 | 52.98 | 4.86 | -3.83 | 26.01 |
EPS (Diluted) | 22.17 | 25.08 | 52.85 | 4.86 | -3.83 | 26.00 |
EPS Growth | -23.46% | -52.54% | 987.45% | - | - | -50.46% |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | - | -2,223 | -435 | 736 | -1,538 | 2,376 |
Free Cash Flow Per Share | - | -13.99 | -2.74 | 4.63 | -9.66 | 14.92 |
Dividend Per Share | - | 5.000 | 5.000 | 5.000 | 5.000 | 5.000 |
Dividend Growth | - | 0% | 0% | 0% | 0% | 0% |
Gross Margin | 65.01% | 65.16% | 64.95% | 64.92% | 66.86% | 75.73% |
Operating Margin | 8.78% | 9.90% | 11.15% | 7.80% | 5.97% | 13.70% |
Profit Margin | 4.09% | 4.81% | 11.60% | 1.15% | -0.97% | 6.75% |
Free Cash Flow Margin | - | -2.69% | -0.60% | 1.10% | -2.45% | 3.88% |
EBITDA | 10,732 | 11,216 | 10,511 | 7,933 | 6,463 | 10,663 |
EBITDA Margin | 12.46% | 13.55% | 14.53% | 11.83% | 10.29% | 17.39% |
D&A For EBITDA | 3,167 | 3,022 | 2,443 | 2,702 | 2,714 | 2,264 |
EBIT | 7,565 | 8,194 | 8,068 | 5,231 | 3,749 | 8,398 |
EBIT Margin | 8.78% | 9.90% | 11.15% | 7.80% | 5.97% | 13.70% |
Effective Tax Rate | 35.65% | 35.27% | 14.71% | 57.36% | 333.45% | 34.49% |
Revenue as Reported | 86,822 | 83,456 | 72,913 | 67,716 | 63,200 | 61,415 |
Advertising Expenses | - | 624 | 687 | 664 | 413 | 259.84 |